Arthneeti
All Q3 FY25 results →
AL

Alivus Life Sciences Ltd

Q3 FY25Pharmaceuticals & Biotechnology

Alivus Life Sciences Q3 FY25 earnings call: Revenue & Margins

Q3 FY25 earnings call: what management guided on revenue, margins and order book.

Price₹1,351
Market cap₹16.3K Cr
P/E26.3
Updated23 Aug 2026
Read4 min read

The short version

Volume growth for Q3 FY'25 was strong at about 18%, despite a ~6% price erosion. Future growth is expected to be driven largely by new product launches; about 50% of revenue in 4-5 years is projected from new launches.

From Alivus Life Sciences Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Volume growth for Q3 FY'25 was strong at about 18%, despite a ~6% price erosion.
  • CDMO business is expected to improve in coming quarters, though it shows cyclical demand. The 4th project has started but contribution is currently small, with more projects expected to commercialize by H1 FY'26.
  • Approximately half of revenue in 4-5 years is expected from new product launches, indicating significant growth from newer portfolios.
  • Stable demand from Europe, Japan, India, and Rest of World is offsetting weaker Americas (US & LATAM), with subdued demand expected in Americas for a couple more quarters.
  • Backward integration efforts are aimed at protecting margins and derisking raw materials supply, which should support stable future growth.

2 more points from Alivus Life Sciences Ltd's call on revenue

Pro opens every point from 15K+ earnings calls

Profitability & Margins

See what Alivus Life Sciences Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Ongoing greenfield expansion at Solapur; significant investment planned.
  • CAPEX for next 3-4 years projected at Rs. 400 to 500 crores.
  • Rs. 33 crores invested in the recent quarter; Rs. 119 crores over nine months FY'25.
  • New R&D center in progress; land securing underway.
  • Early R&D work started on new platforms aiming for commercialization by early FY'27.
  • Capital expenditure aligned with future growth and capacity expansion.

2 more points from Alivus Life Sciences Ltd's call on capex

Pro opens every point from 15K+ earnings calls

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Alivus Life Sciences Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript provided on page 15 and surrounding pages does not explicitly mention the current or expected order book or pending orders in specific terms. However, some relevant insights related to business outlook and demand include: - Increased interest and enquiries for existing commercial products, partly driven by US biosecurity/derisking from China trend. - Newer product launches expected to contribute about half of revenues in 4-5 year horizon. - CDMO business has cyclical demand patterns; recent projects have started but contribution remains modest, with expected improvement in coming quarters. - Steady demand in India, Europe, Japan; subdued demand from US and LATAM regions, partly offset by gains in ROW and others. - Efforts on backward integration to derisk supply base and protect margins.

2 more points from Alivus Life Sciences Ltd's call on order book

Pro opens every point from 15K+ earnings calls

Alivus Life Sciences Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹689 Cr, net profit ₹163 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Alivus Life Sciences Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • SMS Pharma. (Q3 FY25)

    Q3FY25 revenue from operations: ₹173.35 crore, up 7% YoY from ₹161.48 crore in Q3FY24 (Page 18, 5). Key concall takeaways from SMS Pharmaceuticals Ltd's Q3…

  • Wockhardt Ltd (Q3 FY25)

    725 crore, up 2% quarter-on-quarter and 2.2% year-on-year (Q3 FY24 revenue: Rs. Key concall takeaways from Wockhardt Ltd's Q3 FY25 earnings call — and how it…

  • NGL Fine Chem (Q3 FY25)

    Q3FY25 revenue from operations: ₹89.10 crores, a year-on-year (Y-o-Y) increase of 1.30% (Page 8). Key concall takeaways from NGL Fine Chem Ltd's Q3 FY25…

  • Shree Ganesh Rem (Q3 FY25)

    Q3FY25 Revenue from Operations:** ₹27.05 Cr . Key concall takeaways from Shree Ganesh Remedies Ltd's Q3 FY25 earnings call — and how it ranks against sector…

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Alivus Life Sciences Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Alivus Life Sciences Ltd Q3 FY25 results?

Volume growth for Q3 FY'25 was strong at about 18%, despite a ~6% price erosion. Future growth is expected to be driven largely by new product launches; about 50% of revenue in 4-5 years is projected from new launches.

What is Alivus Life Sciences Ltd share price analysis?

Alivus Life Sciences Ltd currently shows a neutral. The stock trades at a P/E of 26.3 with a market cap of ₹16,341 Cr. Investors should review the full earnings analysis for detailed insights.

Is Alivus Life Sciences Ltd planning capital expenditure?

Ongoing greenfield expansion at Solapur; significant investment planned. - CAPEX for next 3-4 years projected at Rs.

Keep Alivus Life Sciences Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.